This past week, EpilepsyCo. Inc. was granted six separate patent applications in the AI Biotech/Diagnostics Sector. All six of the applications teach various aspects of a wearable Epilepsy Control Device. The device monitors brain activity via a small implanted detector. Using AI, the system can predict and detect seizure activity in a person affected by Epilepsy. The implanted detector also has the ability to deliver a lower power ultrasound wave within the brain. When the system detects abnormal activity in the brain associated with an upcoming seizure, it can quickly and autonomously apply a low power ultrasound wave to correct the activity, thereby preventing the seizure before it begins. This system is designed for continuous use, and can even be connected to smartphones or smart watches to provide detailed feedback reports.

Prior to these six applications, EpilepsyCo. Inc only had one other application granted in December of 2019, suggesting the company has been operating in stealth mode until just recently. However, a quick look at their website shows that the company is actually a subsidiary of  4Catalyzer, a medical device incubator company with over 300 scientists, and $600 million in funding. EpilepsyCo. is joining the already crowded AI Biotech/Diagnostic: Neurology sector, and will need to quickly establish its niche if it wants to survive among the other top competitors such as IBM, Facense, and Boston Scientific. However, having access to $600 million and over 300 top scientists certainly helps their chances! Make sure to never miss an update like this by subscribing to Magic Number® AI Biotech/Diagnostics: Neurology Patent Forecast®.